GEG Tech


GEG Tech is a biotechnology company founded in 2013 in Paris, France, specializing in genetic engineering and innovative platforms for gene therapy, immunotherapy, and vaccination. The company invests in R&D, partners with academic and industrial groups, and develops advanced genetic tools and vectors for therapeutic applications. Their mission is to design safe and powerful innovations in genetic engineering, with a focus on cancer immunotherapy, mRNA vaccination, and gene therapy applications.

Industries

biopharma
genetics
life-science

Nr. of Employees

small (1-50)

GEG Tech

Villebon-sur-yvette, Ile-de-France, France, Europe


Products

DNA vector systems (integrating & non‑integrating)

Platform offerings of DNA-based vectors for research and therapeutic applications in both integrating and non-integrating formats.

mRNA vector systems

Proprietary mRNA vector platform intended for applications such as editing delivery and nucleic-acid vaccination.

Protein vector systems (VLPs)

Protein-based delivery vectors such as virus‑like particles for cargo delivery.


Services

Custom vector design and contract production

End-to-end design and production of custom DNA, RNA and protein-based vectors for research and preclinical applications.

Ready-to-use lentiviral vectors (product supply)

Off-the-shelf lentiviral vectors provided for research use to accelerate R&D workflows.

Custom cell line development

Generation of bespoke standard and complex cell lines tailored to experimental requirements.

Transgenic and animal model services

Design and production of genetically defined animal models for in vivo studies.

Recombinant protein bioproduction

Production services for standard and complex recombinant proteins for research and preclinical use.

Collaborative R&D partnerships

Co-development programs and research collaborations with academic and industrial partners leveraging internal vector platforms.

Expertise Areas

  • Viral vector design and manufacturing
  • mRNA therapeutic and vaccine development
  • Genome editing vectorization (CRISPR/prime/base editing)
  • CAR‑T and cancer immunotherapy enablement
  • Show More (5)

Key Technologies

  • Lentiviral vectors
  • DNA integrating and non‑integrating vector systems
  • mRNA vector platforms
  • Virus‑like particle (VLP) vectors
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.